GlassScriptPhysician profile
John Micah H Powers
NPI 1649822545
$2,784.84
in general payments reported to CMS, 2019-2025
30 companies · $855 in 2025
The $855 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.79 · 2021: $81.29 · 2022: $294 · 2023: $604 · 2024: $923 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.42 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $510.80 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $333.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $260.66 | 2023-2025 | Qelbree, Qelbree |
| Abbvie INC. | $226.04 | 2022-2025 | |
| Lilly USA, LLC | $189.11 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $186.69 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.75 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $161.35 | 2023-2025 | |
| Glaxosmithkline, LLC. | $137.55 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.47 | 2022-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $71.10 | 2024-2025 | Xarelto, Spravato |
| Exact Sciences Corporation | $47.59 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $46.05 | 2022-2025 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $39.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.25 | 2022-2025 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $29.71 | 2024 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $23.69 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $22.55 | 2025 | Auvelity |
| Alk-Abello, INC | $21.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $21.29 | 2022 | |
| Verona Pharma, INC. | $18.64 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $17.55 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.76 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $15.12 | 2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $14.32 | 2024 | Horizant |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.10 | 2023 | |
| Organon LLC | $12.54 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Micah Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.